Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
- Conditions
- Interventions
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 531
- Registration Number
- NCT04956692
- Locations
- 🇫🇷
Institut Regional du Cancer de Montpellier - ICM ( Site 1003), Montpellier, Herault, France
🇺🇸St. Bernards Medical Center ( Site 0103), Jonesboro, Arkansas, United States
🇺🇸West Virginia University ( Site 0056), Morgantown, West Virginia, United States
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 550
- Registration Number
- NCT04956640
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, Rhône-Alpes, France
🇯🇵National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
🇦🇺Peninsula and Southeast Oncology, Frankston, Victoria, Australia
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
- Conditions
- Interventions
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Agenus Inc.
- Registration Number
- NCT04943627
- Locations
- 🇦🇲
Hematology Center after prof. R. Yeolyan, Yerevan, Armenia
🇦🇲National Center of Oncology named after V.A. Fanarjian, Yerevan, Armenia
🇺🇸Optimum Research (Southwest Women's Oncology Center), Albuquerque, New Mexico, United States
Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT04892953
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
IBI188 Combination Therapy in Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-04-27
- Last Posted Date
- 2022-10-04
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT04861948
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Tufts Medical Center
- Target Recruit Count
- 83
- Registration Number
- NCT04856176
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
Alvopem® (Pemetrexed) Safety Assessment
- Conditions
- Interventions
- First Posted Date
- 2021-04-13
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- NanoAlvand
- Target Recruit Count
- 199
- Registration Number
- NCT04843007
Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2021-04-08
- Target Recruit Count
- 156
- Registration Number
- NCT04836728
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT04837716
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT04832854
- Locations
- 🇨🇭
Kantonsspital Winterthur; Medizinische Onkologie, Winterthur, Switzerland
🇨🇭UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie, Zürich, Switzerland
🇦🇺Cabrini Hospital Malvern, Malvern, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.